financetom
Business
financetom
/
Business
/
Farmers launch agitation over demand for hike in milk prices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Farmers launch agitation over demand for hike in milk prices
Jul 21, 2020 1:48 AM

Farmers started an agitation in Sangli and Kolhapur districts of western Maharashtra on Tuesday over their various demands, including a hike in milk procurement prices.

The agitators along with members of the Raju Shetti- led Swambhimani Shetkari Sanghatana, a farmers' organisation, stopped milk tankers and emptied them on the Pune-Bengaluru highway passing the two districts.

Talking to PTI, Shetti said they are demanding an increase in milk procurement prices by Rs 5 per litre and the benefit to be directly deposited into the accounts of milk producers.

"We are also demanding an export subsidy of Rs 30 for milk producers and cancellation of the Goods and Services Tax (GST) levied on milk products," he said.

Shetti also demanded cancellation of the Centre's decision to import 10,000 tonnes of milk powder. He said milk business in the state has been affected "because of the policies of the central government".

"Since early morning, members of the Swabhimani Shetkari Sanghatana have been agitating in the region (Sangli and Kolhapur) by stopping the milk tankers and spilling milk on roads," he added.

BJP Pune unit president Jagdish Mulik also said they will to launch a statewide agitation from August 1, if the demands of milk producers are not met. On Monday, BJP leaders in Pune submitted a memorandum of their demands to Collector Naval Kishore Ram.

.

First Published:Jul 21, 2020 10:48 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
Copyright 2023-2025 - www.financetom.com All Rights Reserved